LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Add as a preferred source on Google
NEW YORK, March 28, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased DaVita Inc. (NYSE:DVA) securities between August 5, 2015 and October 21, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/davita-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.
On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis.
If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/davita-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
